-
Leveraging CMS Medicare Data for Oncology RWE: Benefits, Limitations, and Opportunities, and Insights into Enrollment Patterns
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Pembrolizumab as Treatment for FIGO 2014 Stage III-IVA Cervical Cancer in the United States
Mar 10, 2025, 14:00 PM -
GenAI for Critical Appraisal of Evidence for Systematic Literature Reviews (SLRs): A Face-Off between GenAI and Human Reviewers
Mar 10, 2025, 14:00 PM -
Unmet Need in Non-Metastatic Oral Cavity Cancer in the United States: A Targeted Literature Review
Mar 10, 2025, 14:00 PM -
Factors Responsible for Successful Value-Based Agreements and Barriers for Their Adoption in the United States
Mar 10, 2025, 14:00 PM -
Administrative Frequency of Alopecia Areata and Clinical Characteristics in a Colombian HMO: a Real-World Data Characterization For 2015-2023
Mar 10, 2025, 14:00 PM -
Socioeconomic Value of Targeted Therapies for HER2+ Breast Cancer in National Reimbursement Drug List of China
Mar 10, 2025, 14:00 PM -
Integrating Patient-Reported Outcomes in Clinical Care: Opportunities and Roadblocks from the Clinician Perspective: A Scoping Review
Mar 10, 2025, 14:00 PM -
The Clinical Impact of Discontinuation of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2is): A Targeted Literature Review
Mar 10, 2025, 14:00 PM -
Daily Intravenous Ketamine for Treatment-Resistant Depression: a Cost-Effectiveness Analysis Alongside the Clinical Trail
Mar 10, 2025, 14:00 PM -
The Role of Invasive Diagnostics in Prior Authorization for MASH
Mar 10, 2025, 14:00 PM -
Facilitating Effective Implementation of Qualitative in Trial Interviews
Mar 10, 2025, 14:00 PM -
Development of an Online Patient Decision Aid and Culturally Conscious Toolkit for Inflammatory Bowel Disease
Mar 10, 2025, 14:00 PM -
How Well Does Hospital Billing Data Estimate Readmissions and Revision Risks After Spinal Fusion Surgery, Compared to Hospital Billing Linked to Claims Data?
Mar 10, 2025, 14:00 PM -
Assessing Real-World Dosing Patterns for Vesicular Monoamine Transporter-2 Inhibitors (VMAT2i), Valbenazine and Deutetrabenazine, Among Patients with Tardive Dyskinesia (TD) in a Nationwide US Claims Database
Mar 10, 2025, 14:00 PM -
Other Similar Measures? – How Different Really Are QALYs From Life Years, Health Years in Total, and Equal Value Life Years?
Mar 10, 2025, 14:00 PM -
Unmet Needs and Evidence Gaps Among Patients with DLBCL treated with CAR-T Therapy: A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
The Economic Benefit of Biosimilars in North America: A Targeted Literature Review
Mar 10, 2025, 14:00 PM -
How to Mitigate "Carer QALY Trap" when Including Caregiver QOL in Cost-Effectiveness Analysis: A Model Simulation Using Lecanemab in Japanese Patients with Alzheimer's Disease
Mar 10, 2025, 14:00 PM -
Inequities in Access to Oncology Drugs in Brazil - the Case of Public and Private Healthcare Systems
Mar 10, 2025, 14:00 PM
